New Two-Drug attack targets Tough-to-Treat cancers

NCT ID NCT05194995

Summary

This study is testing a new oral drug, JAB-21822, combined with an existing cancer drug called cetuximab. It is for people with advanced colorectal, small intestine, or appendix cancers that have a specific genetic change called KRAS G12C. The main goals are to find a safe and effective dose and to see if the combination can shrink tumors in patients who have already tried at least one standard treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research site01

    Beijing, Beijing Municipality, 100101, China

  • Research site02

    Beijing, Beijing Municipality, 100101, China

  • Research site05

    Zhengzhou, Henan, 450000, China

  • Research site06

    Harbin, Heilongjiang, 150000, China

  • Research site07

    Zhengzhou, Henan, 450000, China

  • Research site08

    Nanchang, Jiangxi, 330000, China

  • Research site09

    Nanjing, Jiangsu, 210000, China

  • Research site11

    Changsha, Hunan, 410000, China

  • Research site12

    Beijing, Beijing Municipality, 100101, China

  • Research site13

    Nanning, Guangxi, 530021, China

  • Research site16

    Linyi, Shandong, 276002, China

  • Research site18

    Wuhan, Hubei, 430079, China

  • Research site19

    Hangzhou, Zhejiang, 310005, China

  • Research site23

    Xi’an, Shanxi, 710000, China

  • Research site28

    Shanghai, Shanghai Municipality, 200032, China

  • Research site29

    Changsha, Hunan, 410000, China

  • Research site31

    Beijing, Beijing Municipality, 100021, China

Conditions

Explore the condition pages connected to this study.